Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 1993-2001

  Prowell, Tatiana M ^a   Blackford, Amanda L ^a   Byrne, Celia ^b   Khouri, Nagi F ^a   Dowsett, Mitchell ^c   Folkerd, Elizabeth ^c   Tarpinian, Karineh S ^a   Powers, Pendleton P ^a   Wright, Laurie A ^a   Donehower, Michele G ^a   Jeter, Stacie C ^a   Armstrong, Deborah K ^a   Emens, Leisha A ^a   Fetting, John H ^a   Wolff, Antonio C ^a   Garrett Mayer, Elizabeth ^d   Skaar, Todd C ^e   Davidson, Nancy E ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTROGEN; ESTRONE SULFATE;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER ADJUVANT THERAPY; CORRELATION ANALYSIS; ESTROGEN BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; ESTROGENS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NITRILES; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 83055174670     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0154     Document Type: Article

References (38)

1. Baum M, Budzar AU, Cuzick Forbes J, Houghton JH, Sahmoud T. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. (Pubitemid 34694019)
2. Goss PE, Ingle JN, Ales-Martinez JE, Chlebowski RT, Wactawski-Wende J, McTiernan A, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
3. Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2010;62:281-93.
4. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
5. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
6. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
7. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density: a hormonally responsive risk factor for breast cancer. J Br Menopause Soc 2006;12:186-93. (Pubitemid 46017608)
8. Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, et al. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011;125: 243-52.
9. Tamimi RM, Hankinson SE, Colditz GA, Byrne C. Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:2641-7. (Pubitemid 41752727)
10. Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, LoSC, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-6. (Pubitemid 32060890)
11. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-76. (Pubitemid 41487804)
12. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-6. (Pubitemid 29508720)
13. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-8. (Pubitemid 38584986)
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
15. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 2010;3:696-706.
16. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with earlystage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
17. Lee JS, Ettinger B, Stanczyk FZ, Vittinghoff E, Hanes V, Cauley JA, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006;91:3791-7. (Pubitemid 44536845)
18. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45. (Pubitemid 38868140)
19. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987;47:1957-61. (Pubitemid 17056706)
20. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 2008;26:1671-6.
21. Lonning PE, Geisler J, Johannessen DC, Ekse D. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J Steroid Biochem Mol Biol 1997;61:255-60. (Pubitemid 27455686)
22. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-7. (Pubitemid 34111382)
23. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol 1994;39:1629-38. (Pubitemid 24306719)
24. Yaffe MJ. Mammographic density. Measurement of mammographic density. Breast Cancer Res 2008;10:209.
25. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-87. (Pubitemid 47233068)
26. Stone J, Gunasekara A, Martin LJ, Yaffe M, Minkin S, Boyd NF. The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 2003;12:625-30. (Pubitemid 36899842)
27. Son HJ, Oh KK. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999;173:905-9.
28. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9. (Pubitemid 29091853)
29. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
30. Pettersen PC, Raundahl J, Loog M, Nielsen M, Tanko LB, Christiansen C. Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist-and computer-based analyses of mammograms. Climacteric 2008;11:135-43. (Pubitemid 351451120)
31. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16. (Pubitemid 34498648)
32. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-20. (Pubitemid 34251947)
33. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 2007;106:75-84. (Pubitemid 47498093)
34. Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, et al. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 2010; 120:427-35.
35. Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, et al. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 2011;126:453-61.
36. Bardia A, Stearns V. Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy. Breast Cancer Res Treat 2010;120:437-9.
37. Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, et al. A polymorphism at the 30- UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010;10:36.
38. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, et al.A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-6. (Pubitemid 351231164)